Last reviewed · How we verify
NCT04621903
A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19
NA trial testing Shanshamani Vati Plus in Covid19 in 26 participants. Completed in 3 November 2020.
27 October 2020
Quick facts
| Lead sponsor | Aarogyam UK |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 26 |
| Start date | 8 October 2020 |
| Primary completion | 27 October 2020 |
| Estimated completion | 3 November 2020 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Shanshamani Vati Plus
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Aarogyam UK — full company profile →
Who can join
Adults 20 to 70, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The COVID-19 pandemic is considered as the most crucial global health concern of the century. Given the complex interaction of physical and social factors on fast spreading infection, there have been increasing calls for comprehensive efforts using a community-based participatory research (CBPR) approach. CBPR partnership composed of representatives from community-based organisations, health and academia actively developed the present study. Specific aims were (1) to assess the efficacy and safety of Ayurvedic combination, Giloy (Tinospora Cordifolia) and Pippali (Piper longum) in the management of mild-to-moderate cases of COVID-19 and (2) to determine the effect in relieving COVID-19 symptoms and preventing the onset of severe infection.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Traditional Herbal Medicines, Bioactive Metabolites, and Plant Products Against COVID-19: Update on Clinical Trials and Mechanism of Actions.
Alam S, Sarker MMR, Afrin S, Richi FT, et al · · 2021 · cited 61× · PMID 34122096 · DOI 10.3389/fphar.2021.671498 -
Ayurvedic formulations: Potential COVID-19 therapeutics?
Mahaboob Ali AA, Bugarcic A, Naumovski N, Ghildyal R. · · 2022 · cited 7× · PMID 35474908 · DOI 10.1016/j.phyplu.2022.100286
Verify or expand the search:
- PubMed search for NCT04621903
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Aarogyam UK trials
Trials by the same sponsor.
- NCT05219357 — Ayurveda Based Intervention for Patients in Acute Psychiatric Crisis Situations · NA · unknown
- NCT04716647 — Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research · NA · completed
- NCT04628130 — Efficacy of Yoga Based Self-Management Program for Chronic Pain · completed
- NCT04315805 — Integrative Yoga Therapy for Patients With Chronic Pain and Psychological Distress · NA · unknown
- NCT04480398 — Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04621903 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aarogyam UK
- Last refreshed: 19 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04621903.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing